Next-generation technology enhances ease-of-use for physicians and streamlines manufacturability
The Company is targeting limited market introduction in Q42020 and commercial launch of the Cerene® Device in the first half of 2021
Emeryville, California, July 21, 2020 – Channel Medsystems® (“Channel”), a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that the U.S. Food and Drug Administration (FDA) recently approved the newest Cerene® Cryotherapy Device, a next-generation technology for the treatment of heavy menstrual bleeding in the office setting.